Teva's Copaxone fails to show greater efficacy at higher dose
This article was originally published in Scrip
Teva Pharmaceutical Industries' Copaxone (glatiramer acetate) has failed to show increased efficacy at a 40mg dose, compared with the licensed 20mg dose, in a Phase III study in relapsing-remitting multiple sclerosis that was looking at reducing the relapse rate.
You may also be interested in...
Amgen's investigational bone loss treatment denosumab more than halves osteoporosis patients' risk of new vertebral fractures, new data from a pivotal Phase III trial show.
GlaxoSmithKlineand Xenoporthave submitted an NDA to the US FDAfor the once-daily restless legs syndrome drug Solzira (gabapentin enacarbil extended-release tablets), previously known as GSK1838262 by GSK and XP13512 by Xenoport.